It was a time for celebration at the US FDA, which approved the first generic alternative to Mylan NV's EpiPen (epinephrine) two years after the company became a poster child for high drug prices. Although much of the criticism had been directed at Mylan for its pricing practices, FDA became a punching bag as well with criticism of its generic drug approval process.
Genentech Inc. picked up a broad breakthrough therapy designation for its anti-IgE antibody Xolair (omalizumab) for the prevention of...
